Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCLG-APL 2021 Venetoclax Debulking Study in Pediatric APL
ChiCTR2300069288Phase 4Recruiting
- Sponsor
- Beijing Children's Hospital
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of venetoclax in Acute promyelocytic leukaemia (APL), sponsored by Beijing Children's Hospital. Primary endpoints: Early mortality, Incidence of complications and 2 more. Started Mar 2023; status: recruiting.
02
Drugs
venetoclax
03
Conditions
Acute promyelocytic leukaemia (APL)
Beyond the preview
Go deeper on ChiCTR2300069288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069288.